HR and breast cancer: Additionally, a recent preclinical study [19] demonstrated that HR+, HER2− breast cancer models resistant to high-dose palbociclib also continued to derive benefit from treatment with abemaciclib, though abemaciclib-resistant models did not benefit from palbociclib treatment.